Nucleotide analogs

Patent metadata

Field	Value
Publication number	US-12521397-B2
Application number	US-202117524334-A
Country	US
Kind code	B2
Filing date	Nov 11, 2021
Priority date	Sep 15, 2014
Publication date	Jan 13, 2026
Grant date	Jan 13, 2026

Abstract

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

First claim

What is claimed is:

1 . A method for the treatment of human papilloma virus in a subject in need thereof comprising administering to the subject an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

2 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3 . The method of claim 2 , wherein the human papilloma virus is high-risk human papilloma virus.

4 . The method of claim 2 , wherein the human papilloma virus is selected from HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

5 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6 . The method of claim 5 , wherein the human papilloma virus is selected from HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

7 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 7 , wherein the human papilloma virus is selected from HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

9 . The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10 . The method of claim 9 , wherein the human papilloma virus is selected from HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

11 . The method of claim 2 , wherein the subject is human.

12 . The method of claim 2 , wherein the compound is administered topically.

13 . The method of claim 2 , wherein the compound is administered as a gel, a cream, or a suppository.

14 . The method of claim 2 , wherein the compound is administered intravaginally.

15 . The method of claim 2 , wherein the compound is administered as a single dose.

16 . The method of claim 2 , wherein the compound is administered as a series of two or more doses.

17 . A method for the treatment of a disease caused by human papilloma virus comprising administering an effective amount of a compound selected from

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a host in need thereof.

18 . The method of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19 . The method of claim 18 , wherein the disease is cervical intraepithelial neoplasia.

20 . The method of claim 19 , wherein the host is human.

21 . The method of claim 19 , wherein the compound is administered topically.

22 . The method of claim 19 , wherein the compound is administered as a gel, a cream, or a suppository.

23 . The method of claim 19 , wherein the compound is administered intravaginally.

24 . The method of claim 19 , wherein the compound is administered as a single dose.

25 . The method of claim 19 , wherein the compound is administered as a series of two or more doses.

26 . The method of claim 18 , wherein the disease is vaginal intraepithelial neoplasia.

27 . The method of claim 18 , wherein the disease is anal intraepithelial neoplasia.

28 . The method of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

29 . The method of claim 28 , wherein the disease is cervical intraepithelial neoplasia.

30 . The method of claim 28 , wherein the disease is vaginal intraepithelial neoplasia.

31 . The method of claim 28 , wherein the disease is anal intraepithelial neoplasia.

32 . The method of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

33 . The method of claim 32 , wherein the disease is cervical intraepithelial neoplasia.

34 . The method of claim 32 , wherein the disease is vaginal intraepithelial neoplasia.

35 . The method of claim 32 , wherein the disease is anal intraepithelial neoplasia.

36 . The method of claim 17 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

37 . The method of claim 36 , wherein the disease is cervical intraepithelial neoplasia.

38 . The method of claim 36 , wherein the disease is vaginal intraepithelial neoplasia.

39 . The method of claim 36 , wherein the disease is anal intraepithelial neoplasia.

Assignees

• Univ California
• Us Gov Veterans Affairs

Inventors

• Hostetler Karl Y
• Beadle James R
• Valiaeva Nadejda

Classifications

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• C07F9/657181

  the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative · CPC title

• A61K8/24

  Phosphorous; Compounds thereof · CPC title

• C07F9/65744

  condensed with carbocyclic or heterocyclic rings or ring systems · CPC title

• C07F9/65742

  non-condensed with carbocyclic rings or heterocyclic rings or ring systems · CPC title